DOCSLIB.ORG

Modern Methods of Contraception in India the Potential of Progestin-Only Pills and Centchroman

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Modern Methods of Contraception in India the Potential of Progestin-Only Pills and Centchroman Modern Methods of Contraception in India The Potential of Progestin-Only Pills and Centchroman April 2016 Table of Contents Executive Summary -------------------------------------------------------------------------------------------------- 3 Introduction ------------------------------------------------------------------------------------------------------------ 5 The Facts ------------------------------------------------------------------------------------------------------------ 7 Progestin-Only Pills -------------------------------------------------------------------------------------------- 7 Centchroman ----------------------------------------------------------------------------------------------------- 8 Introduction of Progestin-Only Pills and Centchroman into the Basket of Choice: considerations --------------------------------------------------------------------------------------------------------- 9 Progestin-Only Pills -------------------------------------------------------------------------------------------- 9 ‐ Global Experiences ---------------------------------------------------------------------------------------- 9 ‐ Global Evidence ------------------------------------------------------------------------------------------- 10 ‐ Indian Scenario -------------------------------------------------------------------------------------------- 13 Centchroman ---------------------------------------------------------------------------------------------------- 11 ‐ Global Experiences --------------------------------------------------------------------------------------- 11 ‐ History in India --------------------------------------------------------------------------------------------- 12 ‐ The Evidence from India -------------------------------------------------------------------------------- 12 ‐ The Opportunities in India ------------------------------------------------------------------------------ 18 Policy considerations: The Way Forward ---------------------------------------------------------------------- 20 ‐ Technical Issues -------------------------------------------------------------------------------------------- 20 ‐ Building the Evidence/Operations Research -------------------------------------------------------- 20 ‐ Introduction of additional methods into the national program ----------------------------------- 21 ‐ Communication Strategy --------------------------------------------------------------------------------- 21 ‐ Multipronged Strategy for Service Delivery ---------------------------------------------------------- 21 ‐ Build and Leverage Public-Private Partnerships --------------------------------------------------- 21 ‐ Task Shifting for Service Delivery ---------------------------------------------------------------------- 21 ‐ Operational Plan for Implementation & Monitoring ------------------------------------------------ 21 References ----------------------------------------------------------------------------------------------------------- 22 2 EXECUTIVE SUMMARY A paradigm shift in India’s national policy from the “population control” approach (focused on sterilization), to a reproductive rights-based approach that seeks to empower couples to take informed decisions about timing of births and family size is evident. Under the National Health Mission (NHM), family planning is now positioned as a critical intervention for improving women’s health and reducing maternal and child mortality. The focus is on increasing access, expanding choices of available methods and improving the quality of family planning services. International data over a period of twenty-seven years shows that expansion of the contraceptive method mix in low and middle-income countries has a positive relationship with contraceptive use. Use of contraception may be increased by extending the availability of current methods, by improving features of current methods, or by introducing new methods. A wider choice of methods also improves the ability to meet the individual needs of women and couples. The strategic framework of the Reproductive Maternal Newborn Child + Adolescent Health (RMNCH + A) program offers a fresh paradigm for family planning interventions. The time is opportune for expanding access of women to a wider modern method-mix of contraceptives. A significant development in the recent past has been policy decisions of the Government of India to expand the basket of choice of modern methods of contraception available in the public health system by introducing newer contraceptives such as the injectable contraceptive Depot Provera or Depot Medroxy Progesterone Acetate (DMPA), the non- steroidal and non-hormonal contraceptive Centchroman, and Progestin – Only Pills (POPs). The exponential increase in institutional deliveries to more than 80%, accords an opportunity to increase the choices on offer to women in the postpartum period. In addition to postpartum sterilization and postpartum Intra Uterine Contraceptive Device, the potential of POPs as a non-invasive option for spacing births in the postpartum period, particularly for breastfeeding women, has been accepted. The recently revised World Health Organization’s Medical Eligibility Criteria (WHO MEC 2015) for contraceptives have endorsed POPs for use in breastfeeding women in the immediate postpartum period (< 6 weeks) as the advantages are said to outweigh the risks during this period. Availability of POPs has till now been restricted to the private sector in India. Centchroman (Ormeloxifene) is another promising option for spacing, referred to as the once-a- week non-steroidal oral contraceptive available under the brand name ‘Saheli’.This was developed indigenously in India by the Central Drug Research Institute in the 1980s, approved for marketing in 1990 and is available at a subsidized rate through the social marketing scheme of the Government of India since 1995. This paper presents the global and national historical experience with POPs and Centchroman as credible methods of reversible contraception. It presents a summary of the scientific evidence that testifies to the safety, efficacy and acceptability of these products and is the basis of the policy initiative of the Government of India to include them in the basket of contraceptive choices for clients in the public health system. It also explores the programmatic opportunities and issues, for consideration, for taking these methods to scale in the country. 3 List of Abbreviations ARC – Advocating for Reproductive Choices ASHA – Accredited Social Health Activist AUB – Abnormal Uterine Bleeding API – Active Pharmaceutical Ingredient BMD – Bone Mineral Density CDRI – Central Drug Research Institute COC – Combined Oral Contraceptive CSIR – Council of Scientific & Industrial Research DCGI – Drug Controller General of India DGHS – Director General of Health Services DLHS – District Level Household Survey DMPA – Depot Medroxy Progesterone Acetate DTAB – Drugs Technical Advisory Board DUB – Dysfunctional Uterine Bleeding FDA – Food and Drug Administration FP – Family Planning FOGSI – Federation of Obstetrical and Gynecological Societies of India ICMR – Indian Council of Medical Research ICT – Information Communication Technology INN – International Nonproprietary Name MEC – Medical Eligibility Criteria mCPR – Contraceptive Prevalence Rate, modern methods MF – Method Failure NGO – Non-Governmental Organisation NHM – National Health Mission OCP – Oral Contraceptive Pill PI – Pearl Index POP – Progestin Only Pills RMNCH+A – Reproductive Maternal Newborn Child and Adolescent Health SIDA – Swedish International Development Cooperation Agency SRS – Sample Registration system TFR – Total Fertility Rate UF – User Failure USG – Ultrasonogram 4 Modern Methods of Contraception in India The Potential of Progestin - Only Pills and Centchroman Introduction Twenty per cent of the world’s eligible couples with an unmet need for contraception live in India. In 2007-08, the country had an unmet need of 21.3 % and only 47.1% of eligible couples were reported to be using a modern method of contraception.12 In 1952, India became the first country in the world to launch a national family planning program. One of the goals enunciated in the National Population Policy 2000, is to stabilize the population at a level consistent with the requirement of the national economy and achieve the replacement level Total Fertility Rate (TFR) of 2.1 by the year 2010.20 Several interventions have contributed to the secular decline of TFR, however it was still 2.3 per woman in the year 2013.8 The high unmet need for family planning and the still relatively high TFR have triggered strategic change over a period of time. A paradigm shift in national policy from the “population control” approach (focused on sterilization), to a reproductive, rights-based approach, that seeks to empower couples to take informed decisions about timing of births and family size, is evident. Under the National Health Mission (NHM), family planning is now positioned as a critical intervention for improving women’s health and reducing maternal and child mortality. The focus is on increasing access, expanding choices of available methods and improving the quality of family planning services. India’s commitments made in the London Summit on Family Planning are articulated in “India’s Vision FP2020”.18 These include: Ensuring access to family planning services to an additional 48 million women by 2020 Increasing financial commitment on family planning to more than
Load more

Recommended publications
  • University of Groningen the Pill and Thrombosis Van Vlijmen, Elizabeth
    University of Groningen The pill and thrombosis van Vlijmen, Elizabeth Femma Willemien IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2016 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): van Vlijmen, E. F. W. (2016). The pill and thrombosis. Rijksuniversiteit Groningen. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne- amendment. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 08-10-2021 Financial support for the printing of this thesis was kindly provided by the Dutch Medicines Evaluation Board and UMCG/GUIDE.
    [Show full text]
  • Lactational Amenorrhea Method
    Lactational Amenorrhea Method Dr. Raqibat Idris [email protected] From Research to Practice: Training in Sexual and Reproductive Health Research 2017 Objectives of presentation • Define Lactational Amenorrhea Method (LAM) • Understand the mechanism of action of LAM • Know the efficacy of LAM • Know and describe the 3 criteria for LAM • Know the indication and contraindications for LAM • Know the focus and timing of counselling for LAM • List the advantages, disadvantages and health benefits of LAM • Know the elements of programming necessary for the provision of quality LAM services Introduction Breastfeeding delays the return of a woman’s fertility in the first few months following childbirth. Women who breastfeed are less likely to ovulate in this period. When compared with women who breastfeed partially or who do not breastfeed at all, women who breastfeed more intensively are less likely to have a normal ovulation before their first menstrual bleed postpartum (Berens et al., 2015). In a consensus meeting in Bellagio, Italy in 1998, scientists proposed that women who breastfeed fully or nearly fully while they remain amenorrhoeic in the first 6 months postpartum experience up to 98% protection from pregnancy. This formed the basis for the Lactational Amenorrhea Method and has since then been tested and confirmed by other studies (Berens et al., 2015; Van der Wijden et al., 2003; WHO, 1999). Berens P, Labbok M, The Academy of Breastfeeding Medicine. ABM Clinical Protocol #13: Contraception During Breastfeeding, Revised 2015. Breastfeeding Medicine. 2015 Feb;10(1):3-12. The World Health Organization multinational study of breast-feeding and lactational amenorrhea. III.
    [Show full text]
  • Levosert 20Microgram/24 Hours Intrauterine Delivery System UK/H/3030/001/DC
    PAR Levosert 20microgram/24 hours Intrauterine Delivery System UK/H/3030/001/DC Public Assessment Report Decentralised Procedure LEVOSERT 20MICROGRAM/24 HOURS INTRAUTERINE DELIVERY SYSTEM (levonorgestrel) Procedure No: UK/H/3030/001/DC UK Licence No: PL 30306/0438 ACTAVIS GROUP PTC ehf 1 PAR Levosert 20microgram/24 hours Intrauterine Delivery System UK/H/3030/001/DC LAY SUMMARY Levosert 20 microgram/24 hours Intrauterine Delivery System (levonorgestrel, intrauterine delivery system, 52mg (20 micrograms/24 hours)) This is a summary of the Public Assessment Report (PAR) for Levosert 20 microgram/24 hours Intrauterine Delivery System (PL 30306/0438; UK/H/3030/001/DC, previously PL 34096/0003; UK/H/3030/001/DC). It explains how Levosert 20 microgram/24 hours Intrauterine Delivery System was assessed and its authorisation recommended, as well as its conditions of use. It is not intended to provide practical advice on how to use Levosert 20 microgram/24 hours Intrauterine Delivery System. For practical information about using Levosert 20 microgram/24 hours Intrauterine Delivery System, patients should read the package leaflet or contact their doctor or pharmacist. Levosert 20 microgram/24 hours Intrauterine Delivery System may be referred to as Levosert in this report. What is Levosert and what is it used for? Levosert is an intrauterine delivery system (IUS) for insertion in the womb. It can be used in the following ways: • as an effective method of contraception (prevention of pregnancy); • for heavy menstrual bleeding (heavy periods). Levosert is also useful for reducing menstrual blood flow, so it can be used if you suffer from heavy menstrual bleeding (periods).
    [Show full text]
  • A History of Birth Control Methods
    Report Published by the Katharine Dexter McCormick Library and the Education Division of Planned Parenthood Federation of America 434 West 33rd Street, New York, NY 10001 212-261-4716 www.plannedparenthood.org Current as of January 2012 A History of Birth Control Methods Contemporary studies show that, out of a list of eight somewhat effective — though not always safe or reasons for having sex, having a baby is the least practical (Riddle, 1992). frequent motivator for most people (Hill, 1997). This seems to have been true for all people at all times. Planned Parenthood is very proud of the historical Ever since the dawn of history, women and men role it continues to play in making safe and effective have wanted to be able to decide when and whether family planning available to women and men around to have a child. Contraceptives have been used in the world — from 1916, when Margaret Sanger one form or another for thousands of years opened the first birth control clinic in America; to throughout human history and even prehistory. In 1950, when Planned Parenthood underwrote the fact, family planning has always been widely initial search for a superlative oral contraceptive; to practiced, even in societies dominated by social, 1965, when Planned Parenthood of Connecticut won political, or religious codes that require people to “be the U.S. Supreme Court victory, Griswold v. fruitful and multiply” — from the era of Pericles in Connecticut (1965), that finally and completely rolled ancient Athens to that of Pope Benedict XVI, today back state and local laws that had outlawed the use (Blundell, 1995; Himes, 1963; Pomeroy, 1975; Wills, of contraception by married couples; to today, when 2000).
    [Show full text]
  • Efficacy of a Selective Estrogen Receptor Modulator: 'Ormeloxifene' in Management of Dysfunctional Uterine Bleeding
    JSAFOG CLINICALEfficacy PRACTICEof a Selective Estrogen Receptor Modulator: ‘Ormeloxifene’ in Management of Dysfunctional Uterine Bleeding Efficacy of a Selective Estrogen Receptor Modulator: ‘Ormeloxifene’ in Management of Dysfunctional Uterine Bleeding 1Tapan Kumar Bhattacharyya, 2Anusyua Banerji 1Professor and Head, Department of Obstetrics and Gynecology, SRMS Institute of Medical Sciences, Bareilly, Uttar Pradesh India 2Senior Resident, RG Kar Medical College, Kolkata, West Bengal, India Correspondence: Tapan Kumar Bhattacharyya, Professor and Head, Department of Obstetrics and Gynecology, SRMS Institute of Medical Sciences, Bareilly-243202, Uttar Pradesh, India, Phone: 09748236960, e-mail: [email protected] Abstract Background: Ormeloxifene, a third generation selective estrogen receptor modulator, has been claimed to ameliorate symptoms of DUB. This study was undertaken to compare the efficacy of ormeloxifene and norethisterone. Methods: 180 cases of DUB, who have completed child bearing and are above 35 years, were randomly assigned ormeloxifene, progesterone and iron groups. Ormeloxifene group received ormeloxifene for 12 weeks. Norethisterone group received norethisterone for 12 days in every cycle for six cycles. Iron was given as 60 mg of elemental iron daily. Before starting drug therapy, ultrasound, office hysteroscopy and endometrium sampling for histopathology was obtained and repeated at end of follow-up. The side effects and complications of drug ormeloxifene were noted and relief of symptoms and patient acceptability were compared with norethisterone. Results: 81.7% in the ormeloxifene administered subjects marked relief of symptoms with significant reduction of PBAC scores, reduction of blood clots, and rise in hemoglobin levels. Side effects/complications included amenorrhea, urinary incontinence and genital prolapse. The ease of administration of ormeloxifene facilitated compliance and acceptability.
    [Show full text]
  • Preven Emergency Contraceptive
    9/1/1998 1 Rx Only PREVENÔ Emergency Contraceptive Kit consisting of Emergency Contraceptive Pills and Pregnancy Test Emergency Contraceptive Pills (Levonorgestrel and Ethinyl Estradiol Tablets, USP) and Pregnancy Test The PREVENÔ Emergency Contraceptive Kit is intended to prevent pregnancy after known or suspected contraceptive failure or unprotected intercourse. Emergency contraceptive pills (like all oral contraceptives) do not protect against infection with HIV (the virus that causes AIDS) and other sexually transmitted diseases. DESCRIPTION The PREVENÔ Emergency Contraceptive Kit consists of a patient information book, a urine pregnancy test and four (4) emergency contraceptive pills (ECPs). The pills in the PREVENÔ Emergency Contraceptive Kit are combination oral contraceptives (COCs) which are used to provide postcoital emergency contraception. Each blue film-coated pill contains 0.25 mg levonorgestrel (18,19-Dinorpregn-4-en-20- yn-3-one, 13-Ethyl-17-hydroxy-, (17a)-(-), a totally synthetic progestogen, and 0.05 mg ethinyl estradiol (19-Nor-17a-pregna-1,3,5, (10)-trien-20-yne-3,17-diol). The inactive ingredients present are polacrilin potassium, lactose, magnesium stearate, hydroxypropyl methylcellulose, titanium dioxide, polyethylene glycol, polysorbate 80 and FD&C Blue No.2 Aluminum Lake. MOLECULES TO BE ADDED The Pregnancy Test uses monoclonal antibodies to detect the presence of hCG (Human Chorionic Gonadotropin) in the urine. It is sensitive to 20 – 25 mIU / mL 9/1/1998 2 CLINICAL PHARMACOLOGY ECPs are not effective if the woman is pregnant; they act primarily by inhibiting ovulation. They may also act by altering tubal transport of sperm and/or ova (thereby inhibiting fertilization), and/or possibly altering the endometrium (thereby inhibiting implantation).
    [Show full text]
  • Reseptregisteret 2013–2017 the Norwegian Prescription Database
    LEGEMIDDELSTATISTIKK 2018:2 Reseptregisteret 2013–2017 Tema: Legemidler og eldre The Norwegian Prescription Database 2013–2017 Topic: Drug use in the elderly Reseptregisteret 2013–2017 Tema: Legemidler og eldre The Norwegian Prescription Database 2013–2017 Topic: Drug use in the elderly Christian Berg Hege Salvesen Blix Olaug Fenne Kari Furu Vidar Hjellvik Kari Jansdotter Husabø Irene Litleskare Marit Rønning Solveig Sakshaug Randi Selmer Anne-Johanne Søgaard Sissel Torheim Utgitt av Folkehelseinstituttet/Published by Norwegian Institute of Public Health Område for Helsedata og digitalisering Avdeling for Legemiddelstatistikk Juni 2018 Tittel/Title: Legemiddelstatistikk 2018:2 Reseptregisteret 2013–2017 / The Norwegian Prescription Database 2013–2017 Forfattere/Authors: Christian Berg, redaktør/editor Hege Salvesen Blix Olaug Fenne Kari Furu Vidar Hjellvik Kari Jansdotter Husabø Irene Litleskare Marit Rønning Solveig Sakshaug Randi Selmer Anne-Johanne Søgaard Sissel Torheim Acknowledgement: Julie D. W. Johansen (English text) Bestilling/Order: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no The report can be downloaded from www.fhi.no Grafisk design omslag: Fete Typer Ombrekking: Houston911 Kontaktinformasjon/Contact information: Folkehelseinstituttet/Norwegian Institute of Public Health Postboks 222 Skøyen N-0213 Oslo Tel: +47 21 07 70 00 ISSN: 1890-9647 ISBN: 978-82-8082-926-9 Sitering/Citation: Berg, C (red), Reseptregisteret 2013–2017 [The Norwegian Prescription Database 2013–2017] Legemiddelstatistikk 2018:2, Oslo, Norge: Folkehelseinstituttet, 2018. Tidligere utgaver / Previous editions: 2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007 2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008 2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler / The Norwegian Prescription Database 2005–2009.
    [Show full text]
  • F.8 Ethinylestradiol-Etonogestrel.Pdf
    General Items 1. Summary statement of the proposal for inclusion, change or deletion. Here within, please find the evidence to support the inclusion Ethinylestradiol/Etonogestrel Vaginal Ring in the World Health Organization’s Essential Medicines List (EML). Unintended pregnancy is regarded as a serious public health issue both in developed and developing countries and has received growing research and policy attention during last few decades (1). It is a major global concern due to its association with adverse physical, mental, social and economic outcomes. Developing countries account for approximately 99% of the global maternal deaths in 2015, with sub-Saharan Africa alone accounting for roughly 66% (2). Even though the incidence of unintended pregnancy has declined globally in the past decade, the rate of unintended pregnancy remains high, particularly in developing regions. (3) Regarding the use of contraceptive vaginal rings, updated bibliography (4,5,6) states that contraceptive vaginal rings (CVR) offer an effective contraceptive option, expanding the available choices of hormonal contraception. Ethinylestradiol/Etonogestrel Vaginal Ring is a non-biodegradable, flexible, transparent with an outer diameter of 54 mm and a cross-sectional diameter of 4 mm. It contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. When placed in the vagina, each ring releases on average 0.120 mg/day of etonogestrel and 0.015 mg/day of ethinyl estradiol over a three-week period of use. Ethinylestradiol/Etonogestrel Vaginal Ring is intended for women of fertile age. The safety and efficacy have been established in women aged 18 to 40 years. The main advantages of CVRs are their effectiveness (similar or slightly better than the pill), ease of use without the need of remembering a daily routine, user ability to control initiation and discontinuation, nearly constant release rate allowing for lower doses, greater bioavailability and good cycle control with the combined ring, in comparison with oral contraceptives.
    [Show full text]
  • U.S. Medical Eligibility Criteria for Contraceptive Use, 2010
    Morbidity and Mortality Weekly Report www.cdc.gov/mmwr Early Release May 28, 2010 / Vol. 59 U.S. Medical Eligibility Criteria for Contraceptive Use, 2010 Adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th edition department of health and human services Centers for Disease Control and Prevention Early Release CONTENTS The MMWR series of publications is published by the Office of Surveillance, Epidemiology, and Laboratory Services, Centers for Introduction .............................................................................. 1 Disease Control and Prevention (CDC), U.S. Department of Health Methods ................................................................................... 2 and Human Services, Atlanta, GA 30333. How to Use This Document ......................................................... 3 Suggested Citation: Centers for Disease Control and Prevention. [Title]. MMWR Early Release 2010;59[Date]:[inclusive page numbers]. Using the Categories in Practice ............................................... 3 Recommendations for Use of Contraceptive Methods ................. 4 Centers for Disease Control and Prevention Contraceptive Method Choice .................................................. 4 Thomas R. Frieden, MD, MPH Director Contraceptive Method Effectiveness .......................................... 4 Peter A. Briss, MD, MPH Unintended Pregnancy and Increased Health Risk ..................... 4 Acting Associate Director for Science Keeping Guidance Up to Date ...................................................
    [Show full text]
  • Lactational Amenorrhea Method (LAM)
    Lactational Amenorrhea Method (LAM) What is the lactational amenorrhea method? Lactational Amenorrhea Method (LAM) is a natural and healthy fertility awareness based method (FABM) of family planning. The LAM is a special FABM that can be used by post-partum, breastfeeding mothers. How does LAM Work? Breastfeeding delays the return of a mother’s ovulation (when the woman’s ovary releases an egg) and may make her infertile for six months or more. LAM is an easy tool for post-partum women to use to avoid a pregnancy if they meet the following criteria: 1. Menstrual bleeding has not resumed; AND 2. The infant is exclusively or nearly exclusively breastfed frequently, day and night; AND 3. The infant is under six months of age Women who meet all 3 criteria are not likely to become pregnant and do not need to use another method of birth control. How effective is LAM in helping couples avoid pregnancy? International research among many different populations has shown that the LAM is 99.5% effective with perfect use and 98% effective with typical use. This means that if a woman and her baby meet all three criteria, and she uses every opportunity to breastfeed her baby, the likelihood of an unintended pregnancy is about 2%.1,2 LAM shows that a mother’s body is very good at giving her the time she needs while she cares for and bonds with her new baby! Can LAM help couples achieve pregnancy? No; the LAM is not designed for this goal, but . If a breastfeeding woman notices that one of the three conditions above is missing, then she would know that pregnancy could be more likely since ovulation may return.
    [Show full text]
  • Mycophenolate: OB-GYN Contraception Counseling Referral
    Current as of 6/1/2013. This document may not be part of the latest approved REMS. OB/GYN CONTRACEPTION COUNSELING LETTER Reference ID: 3194413 Current as of 6/1/2013. This document may not be part of the latest approved REMS. Letter to Ob/Gyn Contraception Counseling ((Date)) ((Recipient’s Name)) ((Recipient’s Address 1)) ((Recipient’s Address 2)) ((City, State, ZIP)) In reference to: My patient ((Patient’s Name)) Reason for the referral: Contraception counseling Dear Dr ((Recipient’s Last Name)): I am writing to you in reference to the above-named patient who is under my care for ((diagnosis)) and ((insert drug information such as drug name, when patient will begin taking the drug, if treatment has already begun, etc)). This medication contains mycophenolate, which is associated with an increased risk of first trimester pregnancy loss and congenital malformations. It is important that this patient receive contraception counseling about methods that are acceptable for use while taking mycophenolate. Prescribers of mycophenolate participate in the FDA-mandated Mycophenolate REMS (Risk Evaluation and Mitigation Strategy) to ensure that the benefits of mycophenolate outweigh the risks. The following table lists the forms of contraception that are acceptable for use during treatment with mycophenolate. Acceptable Contraception Methods for Females of Reproductive Potential Guide your patients to choose from the following birth control options: Option 1 Intrauterine devices (IUDs) Tubal sterilization Methods to Use Patient’s partner had
    [Show full text]
  • U.S. Medical Eligibility Criteria for Contraceptive Use, 2016
    Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 65 / No. 3 July 29, 2016 U.S. Medical Eligibility Criteria for Contraceptive Use, 2016 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS Introduction ............................................................................................................1 Methods ....................................................................................................................2 How to Use This Document ...............................................................................3 Keeping Guidance Up to Date ..........................................................................5 References ................................................................................................................8 Abbreviations and Acronyms ............................................................................9 Appendix A: Summary of Changes from U.S. Medical Eligibility Criteria for Contraceptive Use, 2010 ...........................................................................10 Appendix B: Classifications for Intrauterine Devices ............................. 18 Appendix C: Classifications for Progestin-Only Contraceptives ........ 35 Appendix D: Classifications for Combined Hormonal Contraceptives .... 55 Appendix E: Classifications for Barrier Methods ..................................... 81 Appendix F: Classifications for Fertility Awareness–Based Methods ..... 88 Appendix G: Lactational
    [Show full text]